Your browser doesn't support javascript.
Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19
Ömeroglu, Seyda Kayhan; Temel, Fehminaz; Altun, Dilek; Öztop, Burak.
  • Ömeroglu SK; Izmir Provincial Health Directorate, Izmir, Turkey.
  • Temel F; Republic of Turkey, Ministry of Health, Ankara, Turkey.
  • Altun D; Republic of Turkey, Ministry of Health, Ankara, Turkey.
  • Öztop B; Izmir Provincial Health Directorate, Izmir, Turkey.
Turk J Med Sci ; 51(6): 2827-2834, 2021 12 13.
Article in English | MEDLINE | ID: covidwho-1580295
ABSTRACT
Background/

aim:

Due to the importance of early outpatient treatment to prevent hospitalization and disease progression, we examined the effects of hydroxychloroquine and favipiravir, which were initiated in early period, on the clinical course of COVID-19 outpatients. Materials and

methods:

Data of confirmed COVID-19 outpatients over a 4-month period were analyzed retrospectively. Public Health Management System (HSYS) was used for the case-based follow-up. Patients on antiviral therapy for at least five days, including hydroxychloroquine and / or favipiravir and patients who were followed-up for 30 days were included in this analysis.

Results:

We enrolled 1489 patients in this study. Overall, 775 (52%) patients were male and a mean age of patients was 38.9 ± 11.1 years. Of these patients, 537 of them were received favipiravir, 545 of them were received hydroxychloroquine and 407 of them were received both favipiravir and hydroxychloroquine. Symptoms improvement on the 14th day of follow-up was 1.8 times higher in the group of patients receiving hydroxychloroquine compared to patients who received favipiravir (p = 0.003). On the 3rd day of follow- up, PCR negativity rate was higher in patients who received hydroxychloroquine (p = 0.004). Hospitalization rates were similar in patients receiving favipiravir and hydroxychloroquine (p = 0.144). However, in the presence of pneumonia at the time of diagnosis, the hospitalization rate was 6.6 times higher in patients who received favipiravir than those who received hydroxychloroquine.

Conclusion:

The subgroups of patients treated with hydroxychloroquine and/or favipiravir did not have similar disease severities in our study. Therefore, further studies with homogeneous patient groups to be arranged prospectively are needed.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Amides / SARS-CoV-2 / COVID-19 Drug Treatment / Hydroxychloroquine / Antimalarials Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: Turk J Med Sci Year: 2021 Document Type: Article Affiliation country: Sag-2101-146

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Amides / SARS-CoV-2 / COVID-19 Drug Treatment / Hydroxychloroquine / Antimalarials Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: Turk J Med Sci Year: 2021 Document Type: Article Affiliation country: Sag-2101-146